Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus metronomic vinorebine softgel for first-line advanced driver-negative NSCLC in older adults or ECOG 2 patients
ChiCTR2400080378Phase 2Not yet recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Jan 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and vinorelbine in non-small cell lung cancer (NSCLC), sponsored by Shanxi Cancer Hospital. Primary endpoint: Objective response rate. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
sintilimabvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400080378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080378.